[go: up one dir, main page]

AR051565A1 - DERIVADOS DE IMIDAZO[1, 2 - A]PIRIDINA; MÉTODOS PARA SU PREPARACIoN; COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN Y SU USO EN LA ELABORACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DE ENFERMEDADES E INFECCIONES POR VIH MEDIADAS POR CXCR4. - Google Patents

DERIVADOS DE IMIDAZO[1, 2 - A]PIRIDINA; MÉTODOS PARA SU PREPARACIoN; COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN Y SU USO EN LA ELABORACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DE ENFERMEDADES E INFECCIONES POR VIH MEDIADAS POR CXCR4.

Info

Publication number
AR051565A1
AR051565A1 ARP050103666A ARP050103666A AR051565A1 AR 051565 A1 AR051565 A1 AR 051565A1 AR P050103666 A ARP050103666 A AR P050103666A AR P050103666 A ARP050103666 A AR P050103666A AR 051565 A1 AR051565 A1 AR 051565A1
Authority
AR
Argentina
Prior art keywords
alkyl
independently
het
alkynyl
cycloalkyl
Prior art date
Application number
ARP050103666A
Other languages
English (en)
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of AR051565A1 publication Critical patent/AR051565A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • AIDS & HIV (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)

Abstract

Compuestos que demuestran efectos protectores en las células objetivo de la infeccion de VIH en una manera a fin de unirse específicamente al receptor de quimioquina, y los cuales afectan la union del ligante natural o quimioquina a un receptor tal como CXCR4 y/o CCR5 de una célula objetivo. Métodos de preparacion y composiciones farmacéuticas que los contienen y su uso para la fabricacion de medicamentos para el tratamiento de la infeccion por VIH y otras patologías. Reivindicacion 1: Un compuesto de la formula (1), en donde: t es 0, 1 o 2; cada R independientemente es H, alquil, alquenil, alquinil, haloalquil, cicloalquil, -RaAy, -RaOR10, o -RaS(O)qR10; cada R1 independientemente es halogeno, haloalquil, alquil, alquenil, alquinil, cicloalquil, cicloalquenil, -Ay, -NHAy, -Het, -NHHet, -OR10, -OAy, -OHet, -RaOR10, -NR6R7, -RaNR6R7, -RaC(O)R10, -C(O)R10, -CO2R10, -RaCO2R10, -C(O)NR6R7, -C(O)Ay, -C(O)Het, -S(O)2NR6R7, -S(O)qR10, -S(O)qAy, ciano, nitro, o azido; n es 0, 1 o 2; R2 se selecciona de un grupo que consiste de H, alquil, haloalquil, cicloalquil, alquenil, alquinil, -RaAy, -RaOR5, -RaS(O)qR5, o -Racicloalquil, y en donde R2 no se sustituye con amina o alquilamina; cada R4 independientemente es halogeno, haloalquil, alquil, alquenil, alquinil, cicloalquil, cicloalquenil, -Ay, -NHAy, -Het, -NHHet, -OR10, -OAy, -OHet, -RaOR10, -NR6R7, -RaNR6R7, -RaC(O)R10, -C(O)R10, -CO2R10, -RaCO2R10, -C(O)NR6R7, -C(O)Ay, -C(O)Het, -S(O)2NR6R7, -S(O)qR10, -S(O)qAy, ciano, nitro, o azido; m es 0, 1 o 2; cada R5 independientemente es H, alquil, alquenil, alquinil, cicloalquil, o -Ay; p es 0 o 1; Y es -NR10-, -O-, -C(O)NR10-, -NR10C(O)-, -C(O)-, -C(O)O-, -NR10C(O)N(R10)-, -S(O)q-, -S(O)qNR10-, o -NR10S(O)q-; X es -N(R10)2, - RaN(R10)2, -AyN(R10)2, -RaAyN(R10)2, -AyRaN(R10)2, -RaAyRaN(R10)2, -Het, -RaHet, -HetN(R10)2, -RaHetN(R10)2, -HetRaN(R10)2, -RaHetRaN(R10)2, -HetRaAy, o HetRaHet; cada Ra independientemente es alquileno opcionalmente sustituido con uno o más de alquil, oxo o hidroxil, cicloalquileno opcionalmente sustituido con uno o más de alquil, oxo o hidroxil, alquenileno, cicloalquenileno o alquinileno; cada R10 independientemente es H, alquil, cicloalquil, alquenil, alquinil, cicloalquenil, - Racicloalquil, -RaOH, -RaOR5, -RaNR6R7, o -RaHet; cada uno de R6 y R7 independientemente se seleccionan de H, alquil, alquenil, alquinil, cicloalquil, cicloalquenil, -Racicloalquil, -RaOH, -RaOR5, -RaNR8R9, -Ay, -Het, -RaAy, -RaHet, o -S(O)qR5; cada uno de R8 y R9 independientemente se seleccionan de H o alquil; cada q independientemente es 0, 1 o 2; cada Ay independientemente representa un grupo aril opcionalmente sustituido; y cada Het independientemente representa un grupo heteroaril o heterociclil opcionalmente sustituido; o ésteres o sales farmacéuticamente aceptables de los mismos. Reivindicacion 58: El proceso para preparar un compuesto de la formula (1), en donde t es 1; cada R es H; cada R1 independientemente es halogeno, haloalquil, alquil, alquenil, alquinil, cicloalquil, cicloalquenil, -Ay, -NHAy, -Het, -NHHet, -OR10, -OAy, -OHet, -RaOR10, -NR6R7, -RaNR6R7, -RaC(O)R10, -C(O)R10, -CO2R10, -RaCO2R10, -C(O)NR6R7, -C(O)Ay, -C(O)Het, -S(O)2NR6R7, -S(O)qR10, -S(O)qAy, ciano, nitro, o azido; n es 0, 1 o 2; R2 se selecciona de un grupo que consiste de H, alquil, haloalquil, cicloalquil, alquenil, alquinil, -RaAy, -RaOR5, -RaS(O)qR5 o Racicloalquil; cada R4 independientemente es halogeno, haloalquil, alquil, alquenil, alquinil, cicloalquil, cicloalquenil, -Ay, -NHAy, -Het, -NHHet, -OR10, -OAy, -OHet, -RaOR10, -NR6R7, -RaNR6R7, -RaC(O)R10, -C(O)R10, -CO2R10, -RaCO2R10, -C(O)NR6R7, -C(O)Ay, -C(O)Het, -S(O)2NR6R7, -S(O)qR10, -S(O)qAy, ciano, nitro, o azido; m es 0, 1, o 2; cada R5 independientemente es H, alquil, alquenil, alquinil, cicloalquil, o -Ay; p es 0 o 1; Y es -NR10-, -O-, -C(O)NR10-, -NR10C(O)-, -C(O)-, -C(O)O-, -NR10C(O)N(R10)-, -S(O)q-, -S(O)qNR10-, o -NR10S(O)q-; X es -N(R10)2, - RaN(R10)2, -AyN(R10)2, -RaAyN(R10)2, -AyRaN(R10)2, -RaAyRaN(R10)2, -Het, -RaHet, -HetN(R10)2, -RaHetN(R10)2, -HetRaN(R10)2, -RaHetRaN(R10)2, -HetRaAy, o HetRaHet, cada Ra independientemente es alquileno opcionalmente sustituido con uno o más de alquil, oxo o hidroxil, cicloalquileno opcionalmente sustituido con uno o más de alquil, oxo o hidoxil, alquenileno, cicloalquenileno, o alquileno; cada R10 independientemente es H, alquil, cicloalquil, alquenil, alquinil, cicloalquenil, - Racicloalquil, -RaOH, -RaOR5, -RaNR6R7, o -RaHet; cada uno de R6 y R7 independientemente se seleccionan de H, alquil, alquenil, alquinil, cicloalquil, cicloalquenil, -Racicloalquil, -RaOH, -RaOR5, -RaNR8R9, -Ay, -Het, -RaAy, -RaHet, o -S(O)qR5; cada uno de R8 y R9 independientemente se seleccionan de H o alquil; cada q independientemente es 0, 1 o 2; cada Ay independientemente representa un grupo aril opcionalmente sustituido; y cada Het independientemente representa un grupo heteroaril o heterociclil opcionalmente sustituido; comprendiendo la etapa de reaccionar un compuesto de formula (2), en donde R1 y n es segun se define con respecto a la formula (1) con el compuesto de la formula (3), en donde R2, Ra, R4, R5, Y, X, p y m son segun se define con respecto a la formula (1) bajo condiciones de aminacion reductiva para formar un compuesto de la formula (1).
ARP050103666A 2004-09-02 2005-09-01 DERIVADOS DE IMIDAZO[1, 2 - A]PIRIDINA; MÉTODOS PARA SU PREPARACIoN; COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN Y SU USO EN LA ELABORACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DE ENFERMEDADES E INFECCIONES POR VIH MEDIADAS POR CXCR4. AR051565A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60674204P 2004-09-02 2004-09-02
US61076504P 2004-09-17 2004-09-17

Publications (1)

Publication Number Publication Date
AR051565A1 true AR051565A1 (es) 2007-01-24

Family

ID=36000724

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP050103665A AR050302A1 (es) 2004-09-02 2005-09-01 Derivados de imidazo[1,2-a]piridina
ARP050103666A AR051565A1 (es) 2004-09-02 2005-09-01 DERIVADOS DE IMIDAZO[1, 2 - A]PIRIDINA; MÉTODOS PARA SU PREPARACIoN; COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN Y SU USO EN LA ELABORACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DE ENFERMEDADES E INFECCIONES POR VIH MEDIADAS POR CXCR4.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP050103665A AR050302A1 (es) 2004-09-02 2005-09-01 Derivados de imidazo[1,2-a]piridina

Country Status (16)

Country Link
US (2) US20070232615A1 (es)
EP (2) EP1799671A4 (es)
JP (2) JP2008511669A (es)
KR (2) KR20070053313A (es)
AR (2) AR050302A1 (es)
AU (2) AU2005282753A1 (es)
BR (1) BRPI0514881A (es)
CA (2) CA2579059A1 (es)
IL (1) IL181419A0 (es)
MA (1) MA28872B1 (es)
MX (2) MX2007002679A (es)
NO (2) NO20071366L (es)
PE (2) PE20060656A1 (es)
RU (2) RU2352567C2 (es)
TW (2) TW200612921A (es)
WO (2) WO2006026703A2 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007002679A (es) * 2004-09-02 2007-05-16 Smithkline Beecham Corp Compuestos quimicos.
PE20070946A1 (es) * 2006-01-25 2007-10-16 Smithkline Beecham Corp COMPUESTOS DERIVADOS DE IMIDAZO[1,2-a]PIRIDINA COMO MODULADORES DEL RECEPTOR DE QUIMIOQUINA (CXCR4)
US8618122B2 (en) 2006-05-16 2013-12-31 Ono Pharmaceutical Co., Ltd. Compound having acidic group which may be protected, and use thereof
WO2008016006A1 (fr) 2006-07-31 2008-02-07 Ono Pharmaceutical Co., Ltd. Composé auquel un groupe cyclique est lié par une liaison spiro et son utilisation
US7767826B2 (en) * 2007-10-05 2010-08-03 Pharmatech International, Inc. Process for the synthesis of L-(+)-ergothioneine
CA2704645A1 (en) * 2007-11-09 2009-05-14 The Salk Institute For Biological Studies Non-nucleoside reverse transcriptase inhibitors
CN102675305B (zh) * 2011-03-08 2014-11-12 中国科学院上海药物研究所 一类咪唑并吡啶类化合物及其制备方法和用途
CN103570683B (zh) * 2012-07-30 2018-04-17 中国科学院上海药物研究所 多取代胺类化合物及其制备方法和用途
TWI720451B (zh) 2014-02-13 2021-03-01 美商英塞特控股公司 作為lsd1抑制劑之環丙胺
US9670210B2 (en) 2014-02-13 2017-06-06 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
WO2016007722A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
MX373154B (es) * 2015-04-03 2020-04-22 Incyte Holdings Corp Compuestos heterocíclicos como inhibidores de demetilasa 1 específica de lisina (lsd1).
LT3334709T (lt) 2015-08-12 2025-03-10 Incyte Holdings Corporation Lsd1 inhibitoriaus druskos
JP6864296B2 (ja) 2015-12-14 2021-04-28 エックス４ ファーマシューティカルズ， インコーポレイテッド がんを処置する方法
WO2017106332A1 (en) 2015-12-14 2017-06-22 X4 Pharmaceuticals, Inc. Methods for treating cancer
JP6856648B2 (ja) * 2015-12-15 2021-04-07 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃｘｃｒ４受容体アンタゴニスト
PL3393468T3 (pl) 2015-12-22 2023-01-23 X4 Pharmaceuticals, Inc. Metody leczenia niedoboru odporności
CA3019394A1 (en) 2016-04-08 2017-10-12 X4 Pharmaceuticals, Inc. Methods for treating cancer
JP6994767B2 (ja) * 2016-06-21 2022-01-14 エックス４ ファーマシューティカルズ， インコーポレイテッド Ｃｘｃｒ４阻害剤およびその使用
JP7084624B2 (ja) 2016-06-21 2022-06-15 エックス４ ファーマシューティカルズ， インコーポレイテッド Ｃｘｃｒ４阻害剤およびその使用
ES2870920T3 (es) 2016-06-21 2021-10-28 X4 Pharmaceuticals Inc Inhibidores de CXCR4 y usos de los mismos
IL309069A (en) 2017-02-21 2024-02-01 Univ Emory CXCR4 cytokine receptor modulators and related uses
JP7282786B2 (ja) * 2017-09-25 2023-05-29 シージーンテック （スーチョウ， チャイナ） カンパニー リミテッド Ｃｘｃｒ４阻害剤としてのヘテロアリール化合物、それを用いた組成物及び方法
KR102678977B1 (ko) * 2017-09-25 2024-06-28 씨젠테크 (쑤저우, 차이나) 컴퍼니 리미티드 Cxcr4 저해제로서 헤테로아릴 화합물, 그 조성물 및 이용 방법
EP3768256A4 (en) 2018-03-19 2021-11-24 Emory University PANTROPIC ENTRY INHIBITORS
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
US10968200B2 (en) 2018-08-31 2021-04-06 Incyte Corporation Salts of an LSD1 inhibitor and processes for preparing the same
CA3171250A1 (en) 2020-03-10 2021-09-16 E. Lynne KELLEY Methods for treating neutropenia

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ225152A (en) * 1987-07-17 1990-04-26 Janssen Pharmaceutica Nv Heterocyclically substituted piperidinyl benzamides as pharmaceuticals
JP2004512336A (ja) * 2000-09-15 2004-04-22 アノーメッド　インコーポレイティド ケモカインレセプター結合複素環式化合物
KR20030034184A (ko) * 2000-09-15 2003-05-01 아노르메드 인코포레이티드 케모킨 수용체 결합 헤테로사이클릭 화합물
IL154227A0 (en) * 2000-09-15 2003-07-31 Anormed Inc Chemokine receptor binding heterocyclic compounds
AU9355101A (en) * 2000-09-15 2002-03-26 Anormed Inc Chemokine receptor binding heterocyclic compounds
RU2325387C2 (ru) * 2001-12-21 2008-05-27 Анормед Инк. Гетероциклические соединения с повышенной эффективностью, связывающиеся с рецептором хемокина
CA2520259A1 (en) * 2003-04-11 2004-10-28 Anormed Inc. Cxcr4 chemokine receptor binding compounds
MX2007002679A (es) * 2004-09-02 2007-05-16 Smithkline Beecham Corp Compuestos quimicos.
WO2006036816A2 (en) * 2004-09-24 2006-04-06 Smithkline Beecham Corporation Chemical compounds
EP1919872A4 (en) * 2005-08-31 2009-08-05 Smithkline Beecham Corp CHEMICAL COMPOUNDS

Also Published As

Publication number Publication date
BRPI0514881A (pt) 2008-06-24
NO20071366L (no) 2007-05-31
WO2006028896A3 (en) 2006-04-27
PE20060656A1 (es) 2006-08-24
RU2007106780A (ru) 2008-10-10
RU2352567C2 (ru) 2009-04-20
CA2579059A1 (en) 2006-03-16
CA2578746A1 (en) 2006-03-09
IL181419A0 (en) 2007-07-04
AU2005279835A1 (en) 2006-03-09
WO2006026703A3 (en) 2006-10-05
RU2351592C2 (ru) 2009-04-10
US20070254910A1 (en) 2007-11-01
TW200621754A (en) 2006-07-01
US20070232615A1 (en) 2007-10-04
EP1799671A4 (en) 2009-06-10
WO2006028896A2 (en) 2006-03-16
KR20070053313A (ko) 2007-05-23
MX2007002615A (es) 2007-04-27
JP2008511669A (ja) 2008-04-17
RU2007106779A (ru) 2008-10-10
AU2005282753A1 (en) 2006-03-16
WO2006026703A2 (en) 2006-03-09
KR20070049682A (ko) 2007-05-11
MX2007002679A (es) 2007-05-16
EP1784185A4 (en) 2009-06-03
WO2006026703A8 (en) 2006-05-26
MA28872B1 (fr) 2007-09-03
JP2008511668A (ja) 2008-04-17
PE20060712A1 (es) 2006-08-24
AR050302A1 (es) 2006-10-11
EP1784185A2 (en) 2007-05-16
TW200612921A (en) 2006-05-01
NO20071418L (no) 2007-05-31
EP1799671A2 (en) 2007-06-27

Similar Documents

Publication Publication Date Title
AR051565A1 (es) DERIVADOS DE IMIDAZO[1, 2 - A]PIRIDINA; MÉTODOS PARA SU PREPARACIoN; COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN Y SU USO EN LA ELABORACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DE ENFERMEDADES E INFECCIONES POR VIH MEDIADAS POR CXCR4.
AR050522A1 (es) Derivados de bencimidazol como moduladores de la actividad de los receptores de quimioquina; composiciones farmaceuticas que los contienen; metodos para su preparacion y su uso en la fabricacion de medicamentos para el tratamiento contra infecciones por hiv
AR059197A1 (es) Derivados de indazolo piridina para el tratamiento de hiv
ES2705709T3 (es) Compuestos de isoquinolina para el tratamiento del VIH
AR035664A1 (es) Imidazo[4,5-c]quinolin-4-aminas y tetrahidroimidazo[4,5-c]quinolin-4-aminas, composiciones farmaceuticas que las comprenden, uso de dichos compuestos en la preparacion de medicamentos, e intermediarios utiles en la sintesis de dichos compuestos
AR077328A1 (es) Derivados de oxazina y su uso en el tratamiento de trastornos neurologicos
AR082995A1 (es) Profarmacos que comprenden un conjugado de conector de exendina
PE20120106A1 (es) Moduladores de receptores tipo toll
UY29827A1 (es) 2-amina-pirimidina-4-(2-metil-1-(tetrahidro-2h-piran-4-il)-1-imidazol-5-y1) sustituidas y sus derivados, composiciones farmacéuticas que las contienen, procesos para su preparación y aplicaciones
AR064608A1 (es) Derivados de pirazolo-quinazolina sustituidos, composiciones farmaceuticas que los contienen. proceso para su preparacion y uso de los mismos como agentes anticancer.
UY30438A1 (es) Derivados n-sustituidos de 5-halo-4-[2-alquil-1-sustituidos-1h-imidazol-5-il]pirimidin-2-amina, composiciones-procesos para su preparacion y usos
AR034261A1 (es) Compuestos derivados de pirazol[1,5-a]piridina; composiciones farmaceuticas, su uso en la fabricacion de medicamentos, y metodos de tratamiento de enfermedades mediadas por quinasas
BRPI0507065B8 (pt) derivados de quinolina, composição que os compreende, seu processo de preparação e seu uso como inibidores micobacterianos
AR059016A4 (es) Derivados de aril-isoxazol-4-il-imidazo[1,2-a]piridina, metodo de preparacion, medicamentos que los contienen y usos en el tratamiento de trastornos cognitivos.
BR112014011850A8 (pt) Derivados de aminopirimidina, seus usos, e composição farmacêutica
NI201500160A (es) Derivados 11-hidroxilo de ácidos biliares y conjugados de aminoácidos de los mismos como moduladores del receptor de farnesoid x
UY30183A1 (es) Derivados de quinolina
AR049706A1 (es) Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
AR056511A1 (es) Derivados de 2-aminopirimidinas, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por el receptor de histamina h4
AR029811A1 (es) Un procedimiento para la preparacion de una sal de citalopram, base cristalina de citalopram obtenida por dicho procedimiento y una composicion farmaceutica
UY28578A1 (es) Derivados de amida
MX2009004780A (es) Derivados de quiniclidina de acido (hetero) arilcicloheptano carboxilico como antagonistas del receptor muscarinico.
AR060914A1 (es) Derivados de furopiridina como ligandos receptores de la acetilcolina nicotinica, una composicion farmaceutica que los comprende y su empleo en la manufactura de un medicamento para el tratamiento de una enfermedad mediada por la activacion del receptor alfa7-nicotinico.
RU2014152459A (ru) N-замещенные производные второго поколения противогрибкового антибиотика амфотерицина в и способы их получения и применения
RU2008145714A (ru) Пуриновые производные в качестве активатора аденозинового рецептора

Legal Events

Date Code Title Description
FA Abandonment or withdrawal